Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
|Articles|September 29, 2005
FDA Appointments and Resignations
FDA Appointments and Resignations
Advertisement
It has been a week of turnover at the
Sept. 22. Acting Center for Drug Evaluation and Research (CDER) Deputy Director Douglas Throckmorton appointed to the post permanently.
Sept. 23. FDA Commissioner Lester Crawford resigns. A copy of the resignation is distributed without comment to the media at 4:35 P.M. (The New York Times observes that the timing, late Friday afternoon with a Category 5 hurricane bearing down on the Texas coast, seems intended to reduce reaction.)
Sept. 23. President George Bush names National Cancer Institute Director Andrew C. von Eschenbach, MD, acting FDA commissioner.
Sept. 26. FDA reports that Jonathan Wilkin, director of the Division of Dermatology and Dental Products, is retiring and that deputy director Stanka Kukich would be named acting director.
Sept 26. Hsien-Ming James Hung named director of the Division of Biometrics I, in CDER’s Office of Pharmacoepidemiology and Statistical Science.
–Douglas McCormick
Advertisement
Related to this article
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Advertisement
Advertisement